Arts Syndrome

Arts syndrome is a rare, inherited condition that mainly affects boys. It causes weak muscles from early life, unsteady movement (ataxia), severe hearing loss, poor vision due to optic nerve damage, developmental delay, frequent infections, and sometimes breathing problems. It is “X-linked,” which means the genetic change sits on the X chromosome; boys, who have only one X, are usually more severely affected, while girls who carry the change may have mild or no symptoms. The condition is caused by harmful changes (loss-of-function mutations) in the PRPS1 gene, which provides instructions for making an enzyme called PRPP synthetase-1. This enzyme is needed to make the body’s nucleotides (purines and pyrimidines), which are the basic building blocks for DNA, RNA, and energy molecules like ATP and GTP. When PRPS1 does not work well, cells—especially brain, nerve, immune, and sensory cells—do not get enough nucleotides and energy, and they cannot function or repair themselves normally. NCBI+3MedlinePlus+3MedlinePlus+3

Arts syndrome is a very rare, inherited, X-linked metabolic and neurological disorder that begins in early infancy—mostly in boys. It is caused by harmful (“loss-of-function”) changes in a gene called PRPS1, which provides instructions for an enzyme named PRPP synthetase-1 (PRS-I). This enzyme helps cells make purines and pyrimidines—the building blocks of DNA and RNA—and also helps make energy-carrying molecules such as ATP and GTP. When PRPS1 does not work properly, cells—especially in the brain, nerves, inner ear, and optic nerve—do not produce enough of these essential molecules. Over time, children develop low muscle tone, delayed motor skills, poor balance, weakness of the peripheral nerves, progressive vision loss from optic nerve damage, and sensorineural hearing loss. Many affected boys are prone to frequent infections, and severe cases can be life-limiting if breathing muscles weaken during illness. NCBI+1

Why does it happen?

PRPS1 defects lower the supply of PRPP, a key “starter” molecule for making purines and pyrimidines. Without enough PRPP, the body cannot keep up with the constant need for DNA/RNA building blocks and for energy carriers such as ATP and GTP. Tissues with high energy needs—like the brain, inner ear, optic nerve, peripheral nerves, muscles, and immune cells—are the most sensitive. That is why children with Arts syndrome often show early problems with tone, movement, hearing, vision, and frequent infections. This PRPS1-related spectrum overlaps with two other PRPS1 conditions (CMTX5 neuropathy and X-linked deafness DFN2), which explains why some families show mixed features. NCBI+2Nature+2

---

Another names

• Lethal ataxia with deafness and optic atrophy (historic term used in the medical literature) Orpha

• PRPS1-related disorder (severe end of spectrum) — clinicians now describe Arts syndrome as part of a phenotypic continuum of PRPS1-deficiency disorders that also includes CMTX5 and DFN (X-linked nonsyndromic hearing loss). NCBI

---

Types

Doctors don’t split Arts syndrome into subtypes the way they do for some conditions. Instead, they talk about three PRPS1-related phenotypes on a spectrum of severity. Arts syndrome represents the most severe, early-onset form:

1. Arts syndrome (severe PRPS1 deficiency) – early infancy onset with hypotonia, ataxia, peripheral neuropathy, progressive optic atrophy/retinopathy, and sensorineural hearing loss; infections can be frequent and dangerous in boys. NCBI

2. CMTX5 (Charcot–Marie–Tooth neuropathy type X5) – predominantly peripheral neuropathy with hearing loss and optic neuropathy; usually milder and later onset than Arts syndrome. NCBI

3. DFN/DFNX1 (X-linked nonsyndromic sensorineural hearing loss) – mainly hearing loss, often without the broader neurological picture. NCBI

Clinicians may also describe “classic male” Arts syndrome (typical severe presentation in boys), “attenuated male” (milder features), and symptomatic female carriers with later-onset hearing loss, optic atrophy, or neuropathy due to skewed X-chromosome inactivation. NCBI

---

Causes

Note: In this section, “cause” includes the root genetic defect plus biological mechanisms and modifiers that make the condition appear or worsen. The root cause is one—PRPS1 loss-of-function. The other items explain how and why disease features develop and may vary in severity.

1. Pathogenic PRPS1 variants (mutations). Missense changes in PRPS1 reduce or abolish PRS-I enzyme activity; several specific amino-acid substitutions have been documented in families. PubMed+1

2. X-linked inheritance. Males (one X chromosome) are affected more severely; females may be unaffected or mildly symptomatic depending on X-inactivation. NCBI

3. De novo variants. A new variant can occur in a child without prior family history. (General genetic principle; also reported in PRPS1 literature.) NCBI

4. Reduced de novo purine synthesis. Low PRPP availability impairs building of purine nucleotides required for neuronal function. MedlinePlus

5. Impaired purine salvage pathway. PRPP is also needed to recycle purines; both make total purine supply insufficient in sensitive tissues. MedlinePlus

6. Reduced pyrimidine synthesis. PRPP also feeds into pyrimidine pathways; shortage contributes to impaired RNA/DNA maintenance in rapidly developing systems. MedlinePlus

7. Energy shortfall (ATP/GTP). Lower nucleotide pools mean less ATP/GTP for neuronal signaling and axonal transport. MedlinePlus

8. Optic nerve vulnerability. High metabolic demand of retinal ganglion cells and optic nerve makes them sensitive to nucleotide deficits → progressive optic atrophy. NCBI

9. Inner ear hair cell stress. Sensory hair cells rely on high-energy turnover; chronic nucleotide shortage promotes sensorineural hearing loss. NCBI

10. Peripheral axon degeneration. Long axons need constant nucleotide supply for maintenance; shortage contributes to axonal neuropathy and areflexia. NCBI

11. CNS myelin/white-matter changes. Some individuals show white-matter reduction, reflecting demyelination risk under metabolic stress. NCBI

12. Immune vulnerability. Many boys are “liable to infections,” especially respiratory; acute infections can trigger rapid weakness and respiratory failure. NCBI

13. Genotype–phenotype location effects. Variants near active/allosteric sites tend to cause more severe disease. NCBI

14. Skewed X-inactivation in females. If the X with the healthy PRPS1 is inactivated more often, females can show hearing or vision problems. NCBI

15. Nutrition/illness stress. Intercurrent illness, fasting, or poor intake may unmask or worsen weakness because cells have even fewer nucleotide precursors available. (Mechanistic inference consistent with infection-related decompensation.) NCBI

16. Mitochondrial-energy interplay. Nucleotide deficits stress mitochondrial energy handling in neurons (functional link through ATP/GTP dependence). (Mechanistic explanation aligned with PRPP’s role.) MedlinePlus

17. Developmental demand. Rapid brain/nerve development in infancy increases susceptibility when PRPP supply is inadequate. MedlinePlus

18. Axonal transport failure. Low GTP/ATP impairs microtubule dynamics and transport of cargo along axons → neuropathy and ataxia. (Mechanistic rationale based on nucleotide roles.) MedlinePlus

19. Retinal/optic oxidative stress. Metabolically fragile retinal cells accumulate damage more easily when nucleotide repair pathways are under-supplied. (Mechanistic inference consistent with optic atrophy reports.) NCBI

20. Allelic spectrum effects. The broader PRPS1 spectrum (Arts, CMTX5, DFN) shows how different variant positions change severity—Arts sits at the severe end. Nature

---

Symptoms and signs

1. Low muscle tone (hypotonia). Babies feel “floppy.” They may have trouble lifting the head or sitting on time. This comes from weak signaling between nerves and muscles because cells are low on energy and nucleotides that support growth. NCBI

2. Delayed motor development. Rolling, sitting, crawling, and walking happen later than in peers because both central balance systems and peripheral nerves are affected. NCBI

3. Ataxia (balance and coordination problems). Children may wobble, fall often, or have a wide-based gait as the cerebellum and long nerve pathways struggle to coordinate movement. NCBI

4. Peripheral neuropathy. Weakness in feet and hands, loss of reflexes, and foot drop may appear as axons fail to maintain normal function. NCBI

5. Sensorineural hearing loss. This may be present at birth or develop later; it often progresses. Hearing aids or cochlear implantation may help communication. NCBI

6. Vision loss from optic neuropathy/retinopathy. Vision may slowly worsen in childhood or adolescence as the optic nerve and retina degenerate. NCBI

7. Mild to moderate intellectual disability. Thinking and learning can be affected; early educational support is beneficial. NCBI

8. Areflexia. Doctors often cannot elicit deep tendon reflexes at the ankles/knees, a sign of peripheral nerve involvement. NCBI

9. Fatigability and exercise intolerance. Limited energy at the cellular level makes activity harder and recovery slower. (Mechanistic explanation consistent with nucleotide shortage.) MedlinePlus

10. Frequent respiratory infections. Many boys have repeated colds and chest infections; acute illness can cause sudden muscle weakness and breathing difficulty. NCBI

11. Feeding difficulties in infancy. Poor tone and fatigue can make feeding slow; nutrition support can help growth. (Clinical inference consistent with hypotonia.) NCBI

12. Speech delay. Hearing loss, oral hypotonia, and developmental delay together can slow speech and language. NCBI

13. Gait abnormalities. Wide-based gait or toe walking may reflect balance problems and distal weakness. NCBI

14. Visual signs (nystagmus, color vision changes). Damage to optic pathways can cause shaky eye movements or trouble with color discrimination. NCBI

15. Life-threatening decompensation during illness. In severe disease, infections can precipitate rapid respiratory failure due to weakened muscles. NCBI

---

Diagnostic tests

A) Physical examination (bedside assessment)

1. General pediatric and neurological exam. The doctor looks for low muscle tone, delayed milestones, weak reflexes, and balance problems. This exam documents baseline function and helps guide further testing. NCBI

2. Hearing screens and formal audiology at the bedside. Newborn hearing screening may be failed; bedside checks of response to sound are followed by formal tests. Early identification supports timely hearing support. NCBI

3. Ophthalmology observation. Pupil responses, eye movements, and fundus (back of the eye) are examined; optic disc paleness suggests optic atrophy. NCBI

4. Gait and posture inspection. The clinician watches standing and walking for wide-based gait, foot drop, or frequent falls—simple clues to ataxia and neuropathy. NCBI

5. Growth and nutrition check. Weight, height, and head circumference are tracked; feeding fatigue or poor growth may trigger nutrition support. (Standard pediatric practice aligned with hypotonia context.) NCBI

B) Manual / bedside neurologic tests

6. Romberg test. Standing with feet together and eyes closed reveals sway or instability, signaling sensory ataxia from neuropathy.

7. Heel-to-toe walking and finger-to-nose tests. These quick tasks highlight cerebellar coordination problems seen in ataxia.

8. Reflex testing with a hammer. Absent ankle/knee jerks point to peripheral nerve involvement typical for the syndrome. NCBI

9. Manual muscle strength grading. Simple resistance tests grade weakness, monitor progression, and guide rehab planning.

10. Bedside vision checks. Near/far acuity charts and color plates can show early optic pathway problems before imaging.

(Items 6–10 are standard neurological bedside tests; their clinical relevance in PRPS1 deficiency comes from the characteristic peripheral neuropathy, ataxia, and optic involvement.) NCBI

C) Laboratory and pathological tests

11. Molecular genetic testing of PRPS1. The key diagnostic test. Sequencing looks for pathogenic variants; it confirms the diagnosis and enables family testing and genetic counseling. NCBI

12. Deletion/duplication analysis (MLPA or similar). If sequencing is negative, labs may look for larger missing or extra segments in PRPS1. NCBI

13. Enzyme activity assay (research/limited). Measuring PRS-I activity in fibroblasts or blood cells can support the diagnosis when available; Arts-associated variants show reduced activity. PubMed

14. Metabolic profiling of nucleotides. Some specialty labs assess purine/pyrimidine metabolites to demonstrate pathway disruption consistent with PRPP deficiency. (Mechanistic alignment.) MedlinePlus

15. Immune/infection workup when indicated. Because some boys have frequent infections, clinicians may check blood counts and immunoglobulins to guide supportive care. NCBI

D) Electrodiagnostic tests

16. Nerve conduction studies (NCS). Electrodes test how well signals travel along nerves; Arts syndrome often shows axonal sensorimotor neuropathy with low amplitudes. NCBI

17. Electromyography (EMG). A fine needle records muscle activity; patterns can support neuropathy rather than a primary muscle disease and help track severity. NCBI

18. Auditory brainstem response (ABR). This objective hearing test measures how sound signals move to the brainstem; it helps confirm sensorineural hearing loss in infants. NCBI

E) Imaging tests

19. Brain MRI. Imaging may be non-specific but can show reduced white matter or other changes that align with the clinical picture; MRI also rules out other causes. NCBI

20. Optical coherence tomography (OCT) and eye imaging. These tests visualize thinning of the retinal nerve fiber layer and optic nerve changes, supporting the diagnosis and tracking progression. NCBI

Non-pharmacological treatments (therapies & others)

(Because evidence is limited, recommendations are adapted from expert reviews on PRPS1 disorders and general best practice in neurogenetic conditions. Each item includes a brief purpose and mechanism in simple words.)

1. Early hearing support and cochlear implant evaluation
   Description : Severe hearing loss blocks language and learning. As soon as hearing loss is confirmed, fit powerful hearing aids and provide family training. If hearing is still not enough for speech, a cochlear implant evaluation is essential, ideally within the first 12–18 months, because earlier implantation supports better speech and brain development. Team care includes audiology, ENT surgery, and speech therapy. Families learn device use, daily checks, and strategies to build listening skills in quiet and noisy rooms. Schools should add FM/remote-microphone systems and captioning. Purpose: give the brain clear sound to build language and social skills. Mechanism: external microphones and implanted electrodes bypass damaged inner-ear cells to directly stimulate the hearing nerve, improving access to speech sounds. Orpha

2. Vision rehabilitation and low-vision aids
   Description: Optic atrophy reduces visual signals to the brain. A low-vision clinic can prescribe high-contrast materials, magnifiers, large-print books, lighting adjustments, and orientation-and-mobility training. Teachers of the visually impaired can adapt classroom materials. Purpose: protect functional vision and independence. Mechanism: compensates for signal loss by boosting contrast, magnification, and environmental cues. Orpha

3. Physiotherapy for tone, strength, and balance
   Description: Regular, play-based exercises improve posture, prevent contractures, train safe transfers, and build endurance. Hydrotherapy and task-specific gait training can help wobbly walking. Purpose: support mobility and reduce falls. Mechanism: repetitive practice strengthens muscles and rewires balance pathways. Orpha

4. Occupational therapy for daily living skills
   Description: OT teaches hand skills, feeding, dressing, writing adaptations, and wheelchair/seating when needed. Splints can prevent wrist or thumb collapse. Purpose: increase independence. Mechanism: activity analysis + assistive devices reduce the effort required to complete tasks. Orpha

5. Speech-language therapy
   Description: Therapy targets receptive/expressive language, articulation, and alternative communication (signs, picture systems, or communication devices) if speech is limited. Purpose: secure a reliable communication method early. Mechanism: structured practice builds neural language networks and compensates for sensory barriers. Orpha

6. Infection prevention plan
   Description: Families receive an action plan for fevers, vaccinations per schedule, RSV/flu/COVID prevention, and early antibiotics when appropriate. Consider immunology referral if infections are frequent or severe. Purpose: reduce hospitalizations and protect lungs. Mechanism: vaccines and early treatment lessen pathogen impact; care pathways shorten time to therapy. Orpha

7. Nutritional support and safe swallowing
   Description: Dietitians optimize calories, protein, and fluids; speech therapists assess swallow safety. If aspiration or poor growth occurs, temporary or long-term tube feeding may be needed. Purpose: support growth and reduce chest infections. Mechanism: adequate nutrition strengthens immunity; safe textures limit aspiration. Orpha

8. Respiratory care
   Description: Chest physiotherapy, suction training, airway-clearance devices, and sleep studies when snoring or pauses occur. Purpose: maintain oxygen levels and prevent pneumonia. Mechanism: mechanical clearance and treatment of sleep-disordered breathing protect lung function. Orpha

9. Orthotics and mobility aids
   Description: Ankle-foot orthoses, walkers, or wheelchairs improve safety and energy conservation. Purpose: enable participation at school and home. Mechanism: external support stabilizes weak joints and saves energy for learning. Orpha

10. Educational supports and individualized education plan (IEP)
    Description: Children may need small-group teaching, captioning, sign support, visual schedules, and extra time. Purpose: fair access to learning. Mechanism: removes sensory and motor barriers to curriculum. Orpha

11. Behavioral and family counseling
    Description: Coaching for routines, communication, and coping; caregiver support to reduce burnout. Purpose: sustain family resilience. Mechanism: skills training and stress-reduction improve adherence and quality of life. Orpha

12. Fall-prevention home adaptations
    Description: Railings, non-slip floors, bathroom bars, and clear lighting reduce injuries for children with ataxia. Purpose: safety. Mechanism: environmental design lowers fall risk. Orpha

13. Pain and tone self-management (non-drug)
    Description: Stretching, heat packs, positioning, and relaxation breathing. Purpose: comfort and sleep. Mechanism: decreases muscle stiffness through reflex pathways. Orpha

14. Care coordination
    Description: A named nurse or social worker links audiology, ophthalmology, neurology, genetics, therapy, and school services. Purpose: fewer missed needs. Mechanism: shared plans and regular reviews. Orpha

15. Communication access in healthcare
    Description: Always provide visual supports, interpreters for sign users, and quiet rooms for hearing-aid checks. Purpose: informed consent and better care. Mechanism: reduces information loss during visits. Orpha

16. Sleep hygiene program
    Description: Fixed bedtime, dark cool room, predictable routine, limited screens. Purpose: improve energy and immunity. Mechanism: supports circadian rhythm and hormone balance. Orpha

17. Dental care with feeding challenges
    Description: High-fluoride toothpaste, frequent cleanings, and sensory-friendly visits. Purpose: prevent caries and aspiration risk. Mechanism: lowers oral bacterial load. Orpha

18. Emergency plan and medical alert
    Description: A one-page plan lists diagnosis, airway tips, infection triggers, hearing device info, and contacts. Purpose: faster, safer emergency care. Mechanism: reduces delays and errors in unfamiliar settings. Orpha

19. Genetic counseling for family planning
    Description: Explains X-linked inheritance, carrier testing, and prenatal/PGT options. Purpose: informed choices. Mechanism: targeted genetic testing identifies carriers and recurrence risk. NCBI

20. Peer-support and rare-disease networks
    Description: Linking with other families reduces isolation and shares tips on hearing, vision, and school supports. Purpose: sustained engagement. Mechanism: social learning and practical problem-solving. Rare Diseases

---

Drug treatments

1. S-adenosylmethionine (SAMe)
   Class: methyl-donor (metabolic supplement). Dosage/Timing: doses in reports vary; specialists individualize (often divided daily). Purpose: improve cellular methylation and purine availability. Mechanism: supplies methyl groups and supports purine cycles downstream of PRPP to help energy and immune-cell function. Side effects: GI upset, anxiety/insomnia in some; drug interactions possible. Evidence note (≈150 words): Case series and reports in Arts syndrome showed stabilization or improvement (e.g., immune-cell survival, clinical symptoms). Data are small but promising; expert supervision is essential. ScienceDirect+2Wiley Online Library+2

2. Nicotinamide riboside (NR)
   Class: NAD+ precursor. Dosage: individualized; divided daily. Purpose: support cellular energy and repair. Mechanism: boosts NAD+, which fuels many enzymes, including those important in immune cells and nerves. Side effects: flushing, GI upset; caution with liver disease. Evidence: co-therapy with SAMe improved T-cell survival and clinical stability in Arts syndrome case series. PMC+1

3. Ribose (D-ribose)
   Class: pentose sugar; metabolic support. Dosage: individualized. Purpose: theoretical PRPP replenishment. Mechanism: provides substrate that can feed into nucleotide synthesis pathways. Side effects: GI upset, hypoglycemia risk in large doses. Evidence: used empirically in nucleotide-synthesis disorders; specific Arts-focused evidence limited—specialist use only. NCBI

4. Uridine
   Class: pyrimidine nucleoside. Dosage: specialist-guided. Purpose: support RNA/energy metabolism where salvage pathways remain. Mechanism: augments pyrimidine salvage; may bypass reduced de novo synthesis. Side effects: GI upset. Evidence: rationale from PRPS1 biology; direct Arts data limited. NCBI

5. Broad-spectrum antibiotics (as indicated)
   Class: anti-infectives. Dosage/Timing: per infection and weight. Purpose: treat chest/ear infections quickly. Mechanism: eradicate bacteria to prevent complications. Side effects: vary by drug (e.g., diarrhea, allergy). Evidence: standard of care for recurrent infections in neurogenetic disease. Orpha

6. Inhaled bronchodilators or steroids (if wheeze/airway reactivity)
   Class: respiratory medicines. Dosage: per guidelines. Purpose: ease breathing. Mechanism: relax airways and reduce inflammation. Side effects: tremor, oral thrush (rinse mouth). Evidence: symptomatic benefit in airway disease. Orpha

7. Antipyretics/analgesics (acetaminophen/ibuprofen as appropriate)
   Purpose: comfort during infections; reduce fever that stresses weak children. Mechanism: central COX inhibition or prostaglandin reduction. Cautions: dosing by weight; avoid NSAIDs if contraindicated. Orpha

8. Anticonvulsants (if seizures)
   Class: varies (levetiracetam, etc.). Purpose: control seizures that further impair development. Mechanism: stabilize neuronal firing. Side effects: drug-specific. Evidence: standard neurologic care; not disease-specific. Orpha

9. Spasticity/tone agents (e.g., baclofen)
   Purpose: relieve stiffness and improve comfort and sleep. Mechanism: GABA-B agonism reduces muscle tone. Side effects: sedation, weakness. Evidence: symptomatic management. Orpha

10. Prophylactic antivirals or monoclonal antibodies during high-risk seasons (case-by-case)
    Purpose: reduce severe viral illness. Mechanism: direct antiviral action or passive immunity. Evidence: general pediatric practice for vulnerable children. Orpha

11. Proton-pump inhibitors or reflux medicines (if aspiration risk/reflux)
    Purpose: protect the lungs and comfort feeding. Mechanism: reduce acid exposure. Cautions: use when clearly indicated. Orpha

12. Vitamin D and standard micronutrient repletion
    Purpose: bone, immunity, and energy support. Mechanism: corrects deficiency common in chronically ill children. Evidence: general pediatric standards. Orpha

13. Melatonin (sleep)
    Purpose: improve sleep quality. Mechanism: circadian entrainment. Side effects: morning sleepiness. Orpha

14. Cough-assist devices with bronchodilators (as prescribed)
    Purpose: clear secretions during infections. Mechanism: mechanical insufflation-exsufflation. Evidence: respiratory-care standards in neuromuscular conditions. Orpha

15. Nebulized hypertonic saline (if thick secretions)
    Purpose: thin mucus. Mechanism: draws water into airway lumen. Side effects: cough/bronchospasm. Orpha

16. Vaccinations (per schedule, including influenza/COVID-19)
    Purpose: prevent infections that can be severe in Arts syndrome. Mechanism: adaptive immunity. Side effects: routine, usually mild. Orpha

17. Immunology-guided therapies (selected cases)
    Purpose: evaluate for immune weakness; consider targeted therapies if deficits found. Mechanism: individualized based on labs (e.g., immunoglobulin in specific deficiencies). Evidence: case-by-case; not universal. Orpha

18. Nebulized antibiotics (selected chronic airway cases)
    Purpose: reduce bacterial load in recurrent infections. Mechanism: topical airway antimicrobial effect. Cautions: specialist only. Orpha

19. Antidepressant/anxiolytic therapy for caregivers (when needed)
    Purpose: sustain family care capacity. Mechanism: treats clinical mood/anxiety disorders in caregivers. Evidence: general mental-health practice. Orpha

20. Clinical-trial enrollment (when available)
    Purpose: access to emerging therapies and careful monitoring. Mechanism: structured research protocols. Evidence: essential to build future treatments. PMC

---

Dietary molecular supplements

(Use only under specialist supervision; quality control and interactions matter.)

1. SAMe — discussed above; included here to emphasize its “nutraceutical” nature in some regions. Dose: specialist-guided. Function/Mechanism: methyl-donor supporting purine cycles and cellular methylation. ScienceDirect+1

2. Nicotinamide riboside (NR) — NAD+ precursor; supports energy and repair in immune and nerve cells. Dose: specialist-guided. Mechanism: raises NAD+. PMC

3. Ribose — substrate for PRPP pathways; theoretical support. Dose: specialist-guided. Mechanism: feeds nucleotide synthesis. NCBI

4. Uridine — supports pyrimidine salvage when de novo synthesis is limited. Dose: specialist-guided. Mechanism: boosts RNA-related pathways. NCBI

5. Nicotinamide (NAM)/Niacin (as alternatives to NR) — increase NAD+ pools; Mechanism: vitamin B3 pathways. PMC

6. L-carnitine — supports mitochondrial fatty-acid transport; Mechanism: may help energy in neuromuscular disease; evidence in Arts is indirect. Orpha

7. Coenzyme Q10 — electron-transport cofactor; Mechanism: supports mitochondrial ATP production; evidence in Arts is extrapolated. Orpha

8. Omega-3 fatty acids — anti-inflammatory; Mechanism: membrane fluidity and eicosanoid balance; may help general neurodevelopmental health. Orpha

9. Vitamin D — immune and bone health; Mechanism: correct deficiency to support resilience. Orpha

10. Multivitamin with trace minerals — backstop against deficiencies in children with feeding difficulties. Mechanism: supports many enzyme systems. Orpha

---

Immunity booster / regenerative / stem-cell–oriented drugs

Because Arts syndrome arises from a basic enzyme deficiency, there is no proven stem-cell or gene therapy yet. The most evidence for disease-level impact concerns SAMe + NR co-therapy improving immune-cell survival; other items below are supportive or experimental concepts only and should be specialist-led. PMC

1. S-adenosylmethionine (SAMe) — see above. Dose: specialist-guided. Function: supports methylation and purine cycles; Mechanism: metabolic augmentation. ScienceDirect

2. Nicotinamide riboside (NR) — see above. Function: raises NAD+; Mechanism: supports mitochondrial and nuclear enzymes. PMC

3. Immunoglobulin replacement (for documented antibody deficiency only) — Function: passive immunity; Mechanism: provides pooled antibodies to prevent severe infections. Note: only if formal testing proves need. Orpha

4. Hematopoietic stem-cell transplantation (HSCT) — Function: theoretical if a clear immune-cell defect is primary; Mechanism: replaces blood/immune system; Status: no established role in Arts syndrome; high risk; research context only. Orpha

5. Nicotinamide (plain B3) as an NAD+ strategy — Function: support NAD+ where NR is unavailable. Mechanism: vitamin pathway to NAD+. Status: extrapolation. PMC

6. Future gene-targeted therapy (concept) — Function/Mechanism: correct or bypass PRPS1 defect; Status: none approved yet; families may explore registries/trials. NCBI

---

Surgeries (when and why)

1. Cochlear implantation — for severe/profound hearing loss not helped by hearing aids. Procedure: implant an electrode into the inner ear with a receiver under the skin. Why: to provide the brain with clear electrical sound signals to develop language. Orpha

2. Gastrostomy tube placement — when unsafe swallowing or poor weight gain persists. Procedure: small feeding tube placed into the stomach. Why: secure nutrition and lower aspiration risk. Orpha

3. Tracheostomy (rare, severe cases) — for chronic airway protection or ventilation. Why: stabilize breathing in refractory respiratory failure. Orpha

4. Strabismus or low-vision–related ophthalmic procedures (select cases) — Why: align eyes or optimize remaining vision to aid development. Orpha

5. Orthopedic procedures (contracture release, spine support) in advanced motor impairment — Why: improve positioning, comfort, and care. Orpha

---

Preventions

1. Keep all vaccines up to date; add annual flu and COVID-19 boosters as advised. Orpha

2. Treat fevers and infections early; use your written action plan. Orpha

3. Protect hearing devices from moisture/impact; check batteries daily. Orpha

4. Use hand hygiene and avoid sick contacts during outbreaks. Orpha

5. Maintain good sleep and nutrition for immune strength. Orpha

6. Provide safe home layouts to reduce falls. Orpha

7. Avoid ototoxic drugs when possible; confirm with your doctor. Orpha

8. Regular audiology and ophthalmology follow-up to catch changes early. Orpha

9. Keep dental care regular to lower chest infection risk from aspiration. Orpha

10. Plan seasonal respiratory precautions (masks in crowded indoor spaces during surges, as advised locally). Orpha

---

When to see a doctor (red flags)

See your doctor or go to urgent care if your child has breathing difficulty, fast breathing, blue lips, or pauses in breathing; fever that is high or persistent; reduced feeding, vomiting, or signs of dehydration; new seizures or long unresponsiveness; sudden hearing or vision changes; worsening weakness, repeated falls, or trouble swallowing; or if a cochlear implant stops working or there is redness/pain at implant or feeding-tube sites. Prompt care prevents serious complications. Orpha

---

What to eat and what to avoid

What to eat: balanced meals with enough calories and protein; plenty of fluids; fruits and vegetables for vitamins; calcium and vitamin D sources for bones; soft, safe textures if swallowing is hard; and dietitian-approved high-calorie shakes if weight gain lags. What to avoid: choking-risk textures if swallowing is unsafe; very salty or sugary “empty-calorie” foods that crowd out nutrition; and unapproved mega-doses of supplements. All new supplements (including SAMe/NR, ribose, uridine) should be reviewed by your specialist team to avoid interactions and to ensure quality products. Orpha

---

FAQs

1) Is Arts syndrome the same in every child?
No. It is a spectrum. Some children have earlier and more severe problems; others are milder. This variability is typical of PRPS1-related disorders. NCBI

2) Why mostly boys?
The PRPS1 gene is on the X chromosome. Boys have one X and are usually more affected; girls may be carriers with milder features. NCBI

3) What testing confirms it?
Genetic testing that finds a disease-causing change in PRPS1. Enzyme testing may support the diagnosis in some labs. NCBI

4) Can my child get better with time?
Supportive care can improve function and quality of life. Some reports show clinical stability or gains with SAMe + NR, but results vary and research is ongoing. PMC

5) Are there approved cures or gene therapies?
Not yet. Research is active. Families can ask about registries and trials. NCBI

6) Does SAMe or NR help everyone?
We do not know. Evidence comes from small case series; specialist supervision is needed. PMC

7) What about uridine or ribose?
These have a biological rationale in PRPS1 deficiency but limited Arts-specific human data. NCBI

8) Is Arts syndrome related to other PRPS1 conditions?
Yes—CMTX5 neuropathy and X-linked hearing loss DFN2 are on the same spectrum of PRPS1-related disorders. Nature+1

9) Could a girl be affected?
Yes, but usually milder due to X-inactivation; some girls have significant symptoms. NCBI

10) Will my child need surgery?
Some children benefit from cochlear implants or feeding tubes for safety and growth. Decisions are individualized. Orpha

11) How often should hearing and vision be checked?
At diagnosis, then regularly (often every 3–6–12 months depending on age and devices). Your team will set a schedule. Orpha

12) Can infections be prevented?
Vaccines, early treatment plans, good sleep and nutrition, and sometimes specialist immunology support help reduce infections. Orpha

13) Are there special school supports?
Yes: IEPs, captioning/remote microphones, low-vision materials, extra time, and therapy services. Orpha

14) What is the long-term outlook?
Outcomes vary. Early diagnosis, strong infection control, and hearing/vision supports can improve comfort, learning, and participation. Orpha

15) Where can I read more?
See GeneReviews (PRPS1-related disorders), Orphanet and NORD pages, and the SAMe+NR case-series reports listed below. PMC+3NCBI+3Orpha+3

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 23, 2025.